Sickle Cell Diseases Treatment Market | Size | Share | Forecast 2018 -2024

14/giu/2018 11:14:50 PBIGP Contatta l'autore

Questo comunicato è stato pubblicato più di 3 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.


Sickle Cell Diseases Treatment Market report offers Market Size, Dynamics, Regional Market Share, Top Key Players, Latest trends, Growth factors, Industry Stats, Historic Market, Business Intelligence, Business Research Reports, Competitive Intelligence 2013 to 2017 and Forecast 2018 to 2024


Sickle cell disease treatment market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as under developed economies. In addition to this unmet needs are highly available, rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.


A sample of this report is available upon request @



Sickle Cell Diseases Treatment Market is segmented on the basis of disease type, therapy, drug class, distribution channel, and geography.


On the basis of disease type, the global sickle cell disease market treatment is segmented as:

·         Sickle beta thalassemia

·         Sickle hemoglobin C disease

·         Sickle cell anemia

·         Others


On the basis of therapy, the global sickle cell disease treatment market is segmented as:

·         Bone Marrow Transplant

·         Blood Transfusion

·         Gene Therapy


On the basis of the drug class, the global sickle cell disease treatment market is segmented as:

·         Antibiotics

·         Analgesics

·         Antimetabolite (Hydroxyurea)

·         Others


On the basis of the distribution channel, the global sickle cell disease treatment market is segmented as:

·         Hospital Pharmacies

·         Retail Pharmacies

·         Others



To view TOC of this report is available upon request @



Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers has moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers has replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.


Need more information about this report @



Based on the geographical regions, global sickle cell diseases treatment market is segmented into Latin America, Europe, North America, the Middle East and Africa, and Asia Pacific. North America is dominating the sickle cell anaemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure, and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in Asia pacific and African regions is favouring the growth of SCD treatment market. Asia-Pacific is one of the speedy growing market due to the funding of the various industry players for stem cell research


Some of the sickle cell disease treatment providers are Biogen (U.S.), Gamida Cell (Israel), Genetix Pharmaceuticals Inc. (U.S.), Sangamo Biosciences (U.S.), Alnylam Pharmaceuticals, Inc. (U.S.), Acceleron Pharma (U.S.), Global Blood Therapeutics Inc. (U.S.), Emmaus Medical, Inc. (U.S.), Novartis AG (Switzerland) and Bristol-Myers Squibb Company (U.S.).


Get access to full summary @



About Precision Business Insights


Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.


Contact to Precision Business Insights,


Kemp House,

152 – 160 City Road,

London EC1V 2NX




Toll Free (US): +1-866-598-1553

Website @


blog comments powered by Disqus è un servizio offerto da Factotum Srl